secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001818331-26-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M
--------------------------------------------------------------------------------

- Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).
- Exome/genome volume 27,488 (+34% YoY); adjusted gross margin 69% flat YoY.
- GAAP net loss $63.3M; adjusted net loss $8.2M vs adjusted net income $9.2M in Q1 2025.
- Full-year 2026 revenue guidance $475-$490M with at least 30% exome/genome volume growth; cash $171.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833126000039/0001818331-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833126000039/wgs-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001818331-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer